Aspirin and Cancer

Patrignani, Paola; Patrono, Carlo

doi:10.1016/j.jacc.2016.05.083

Cited by 217 publications

(203 citation statements)

References 49 publications

Supporting

Mentioning

191

Contrasting

Unclassified

Order By: Relevance

“…Aspirin users were categorized in “high dosage users” (≥300 mg) and “low dosage users” (≤160 mg) 29 . Statin users were categorized in “low-dosage users” (<20 mg) and “moderate/high dosage users” (≥20 mg) based on median value.…”

Section: Methodsmentioning

confidence: 99%

Exclusive and Combined Use of Statins and Aspirin and the Risk of Pancreatic Cancer: a Case-Control Study

Archibugi

Piciucchi

Stigliano

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Data on the association between aspirin and statin use and Pancreatic Ductal AdenoCarcinoma (PDAC) risk are conflicting. These drugs are often co-prescribed, but no studies evaluated the potential combined or confounding effect of the two at the same time. We aimed to investigate the association between aspirin and statin exclusive and combined use and PDAC occurrence. Data on environmental factors, family and medical history were screened in a case-control study. PDAC cases were matched to controls for age and gender. Power calculation performed ahead. Odds ratios (OR) and 95% confidence intervals(CI) were obtained from multivariable logistic regression analysis. In 408 PDAC patients and 816 matched controls, overall statin (OR 0.61; 95%CI,0.43–0.88), but not aspirin use was associated to reduced PDAC risk. Compared to non-users, exclusive statin (OR 0.51; 95%CI,0.32–0.80) and exclusive aspirin users (OR 0.64; 95%CI,0.40–1.01) had reduced PDAC risk. Concomitant statin and aspirin use did not further reduce the risk compared with statin use alone and no interaction was evident. Statin protective association was dose-dependent, and consistent in most subgroups, being stronger in smokers, elderly, obese and non-diabetic patients. The present study suggests that statin use is associated to reduced PDAC risk, supporting a chemopreventive action of statins on PDAC.

show abstract

Section: Methodsmentioning

confidence: 99%

Exclusive and Combined Use of Statins and Aspirin and the Risk of Pancreatic Cancer: a Case-Control Study

Archibugi

Piciucchi

Stigliano

et al. 2017

Sci Rep

View full text Add to dashboard Cite

show abstract

“…This is strongly supported by the clinical efficacy of the antiplatelet agent lowdose aspirin to reduce the incidence and mortality for cancer (14).…”

Section: Platelets Induce Phenotypic Changes Of Cellsmentioning

confidence: 90%

Therapeutic targeting of dysregulated cellular communication

et al. 2017

Self Cite

View full text Add to dashboard Cite

“…The search for related biomarkers is rapidly progressing and will allow to select patients at higher risk of colorectal cancer, with or without specific family history. 12 …”

Section: Low-dose Aspirin and Prevention Of Cancermentioning

confidence: 99%

Use and Misuse of Aspirin in Primary Cardiovascular Prevention

Coccheri

2017

Clin Med Insights Cardiol

View full text Add to dashboard Cite

The use of low-dose aspirin in primary prevention of cardiovascular (CV) events in healthy or apparently healthy people is a widely debated topic. Many arguments indicate that “primary prevention” is only a conventional definition and that the transition from primary to secondary prevention represents a continuum of increasing levels of CV risk. Although there are no direct proofs of a different efficacy of aspirin at different CV risk levels, in low-risk populations aspirin will appear to be less efficient. In fact, the lower number of events occurring in patients at low risk yields lower absolute numbers of events prevented. As many as 6 meta-analyses of trials of primary CV prevention with aspirin versus placebo, performed between 2009 and 2016, confirmed the above concepts and showed a concordant, significant reduction in nonfatal myocardial infarction, with no significant effects on stroke, as well as on CV and all-cause mortality. The recent demonstration of a moderate protective effect of aspirin on cancer (especially colorectal) confers, however, additional value to the use of aspirin, although unusually long durations of treatment and optimal daily compliance seem to be necessary. Because aspirin increases the bleeding risk, the evaluation of its net clinical benefit is an important point of debate. Thus, it is justified to search for a cutoff level of global CV risk above which the net clinical benefit of aspirin becomes evident. Such a threshold value has been calculated considering the data of 9 primary prevention trials, by the Thrombosis Group of the European Society of Cardiology, and has been indicated as a risk value of 2 or more major CV events per 100 persons per year. Also, in the recent 2016 US Guidelines, the main criterion adopted for the indication of aspirin is the level of global CV risk (suggested cutoff is 1 or more major CV events per 100 persons per year). Beyond the different values selected, it is seems very important to introduce to clinical practice and future trials a new criterion based on the level of global CV risk.

show abstract

Aspirin and Cancer

Cited by 217 publications

References 49 publications

Exclusive and Combined Use of Statins and Aspirin and the Risk of Pancreatic Cancer: a Case-Control Study

Exclusive and Combined Use of Statins and Aspirin and the Risk of Pancreatic Cancer: a Case-Control Study

Therapeutic targeting of dysregulated cellular communication

Use and Misuse of Aspirin in Primary Cardiovascular Prevention

Contact Info

Product

Resources

About